Skip to content

Eli Lilly’s Tabalumab Receives FDA Orphan Drug Designation For Multiple Myeloma

November 23, 2012

       On November 19, 2012, Eli Lilly’s Tabalumab receives FDA Orphan Drug Designation (ODD) for the treatment of Multiple Myeloma (MM). 

Facts about Multiple Myeloma : 

–  A hematologic cancer or cancer of the blood 

–  2nd most common blood cancer after non-Hodgkin’s Lymphoma 

–  American Cancer Society estimates 21,700 new cases in 2012. 

References Tabalumab Clinical Trial 

International Myeloma Foundation  

Lilly Oncology Pipeline, Tabalumab (LY2127399)  

Multiple Myeloma Research Foundation (MMRF)  

Copyright © 2012-2013, Orphan Druganaut Blog.  All rights reserved.

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: